Protara Therapeutics Stock Alpha and Beta Analysis
| TARA Stock | USD 2.94 0.34 13.08% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Protara Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Protara Therapeutics over a specified time horizon. Remember, high Protara Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Protara Therapeutics' market risk premium analysis include:
Beta 0.23 | Alpha 0.56 | Risk 4.33 | Sharpe Ratio 0.16 | Expected Return 0.68 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Protara |
Protara Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Protara Therapeutics market risk premium is the additional return an investor will receive from holding Protara Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Protara Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Protara Therapeutics' performance over market.| α | 0.56 | β | 0.23 |
Protara Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Protara Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Protara Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Protara Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Protara Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Protara Therapeutics shares will generate the highest return on investment. By understating and applying Protara Therapeutics stock market price indicators, traders can identify Protara Therapeutics position entry and exit signals to maximize returns.
Protara Therapeutics Return and Market Media
The median price of Protara Therapeutics for the period between Thu, Aug 29, 2024 and Wed, Nov 27, 2024 is 1.93 with a coefficient of variation of 15.7. The daily time series for the period is distributed with a sample standard deviation of 0.33, arithmetic mean of 2.08, and mean deviation of 0.28. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Insider Trading | 09/05/2024 |
2 | Disposition of 1900 shares by Opaleye Management Inc. of Protara Therapeutics at 1.8947 subject to Rule 16b-3 | 09/09/2024 |
3 | Disposition of 1500 shares by Opaleye Management Inc. of Protara Therapeutics at 1.769 subject to Rule 16b-3 | 09/10/2024 |
4 | Disposition of 1600 shares by Opaleye Management Inc. of Protara Therapeutics at 1.7141 subject to Rule 16b-3 | 09/11/2024 |
5 | Disposition of 6500 shares by Opaleye Management Inc. of Protara Therapeutics at 1.7089 subject to Rule 16b-3 | 09/12/2024 |
6 | Dockworkers Reach Deal To End Massive East Coast Strike | 10/04/2024 |
7 | Disposition of 3500 shares by Opaleye Management Inc. of Protara Therapeutics at 2.4419 subject to Rule 16b-3 | 10/30/2024 |
8 | Protara Therapeutics Stock Price Up 0.8 percent Still a Buy | 11/08/2024 |
9 | Protara Therapeutics Q3 Earnings Snapshot | 11/12/2024 |
10 | Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of U... | 11/15/2024 |
11 | Disposition of 500 shares by Opaleye Management Inc. of Protara Therapeutics at 3.0021 subject to Rule 16b-3 | 11/22/2024 |
About Protara Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Protara or other stocks. Alpha measures the amount that position in Protara Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2020 | 2021 | 2022 | 2023 (projected) | PB Ratio | 0.88 | 0.47 | 0.3 | 0.31 | Capex To Depreciation | 4.51 | 5.09 | 0.48 | 0.13 |
Protara Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Protara Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Protara Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Protara Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Protara Therapeutics. Please utilize our Beneish M Score to check the likelihood of Protara Therapeutics' management manipulating its earnings.
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Protara Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Protara Therapeutics Backtesting, Protara Therapeutics Valuation, Protara Therapeutics Correlation, Protara Therapeutics Hype Analysis, Protara Therapeutics Volatility, Protara Therapeutics History and analyze Protara Therapeutics Performance. For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Protara Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.